AIV Logo AIV Assistant

 Logo ANGLE plc - AGL.L 7.25 GBX

EPS
-0.07
P/B
180.92
ROE
-63.75
Beta
0.26
Target Price
44.00 GBX

7.250 GBX

7.250 GBX

Daily: -44.23%
Key Metrics

EPS: -0.07

Book Value: 0.08

Price to Book: 180.92

Debt/Equity: 17.22

% Insiders: 16.183%

Growth

Revenue Growth: -0.14%

Estimates

Forward P/E: -292.99

Forward EPS: -3.65

Target Mean Price: 44.00

 Logo About ANGLE plc - (AGL.L)

Country: United Kingdom

Sector: Health Care

Website: http://www.angleplc.com

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with high analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal transition; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including enumeration of epithelial and mesenchymal CTC populations; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. ANGLE plc has a strategic partnership with Bio View Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use its proprietary pan-cancer next generation sequencing (NGS) panel. The company was founded in 1994 and is based in Guildford, the United Kingdom.

Exchange Ticker
LSE (United Kingdom) AGL.L
PNK (United States) ANPCF

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion